HIV / AIDs - Thailand Medical News

START Study Shows That Initiating ART For Individuals With Low Viral Loads Has More Benefits In The Long Term

Source: Thailand Medical News Jul 15, 2019

Findings from the recent START study involving 4684 adult HIV-positive patients from various countries showed that starting antiretroviral therapy (ART) has significant benefits and entails few risks for individuals with a low pre-treatment viral load. All the patients in the study had a CD4 cell count above 500 cells/mm3 and were randomised to start immediate ART or to defer therapy until th...

Discovery Of New Type of Immune Cells,CD11c+, Leads To New HIV Treatment Strategy

Source: Thailand Medical News Jun 22, 2019

New immunity cells known as CD11c+ dendritic cells have been identified by a team of researchers from The Westmead Institute For Medical Research in Sydney.These CD11c+ dendritic cells are extremely susceptible to the HIV virus and can transmit the virus to other cells especially the CD4 T Cells. These CD11c+ dendritic cells are a type of dendritic cells that play a role in capturing any i...

Keytruda, An Immunotherapy Drug Safe For Treating HIV Patients With Cancer

Source: Thailand Medical News Jun 04, 2019

Most HIV patients have a 60% risk of developing a form of cancer during their life-span. Cancers like Lymphoma, Lung Cancer, Anal Cancer, Cervical Cancer, Oral and oropharyngeal cancer ,liver cancer, skin cancer and also Kaposi's sarcoma are most prevalent among HIV patients. At the recent ASCO presentation, study led by doctors at Fred Hutchinson Cancer Research Center showed that pati...

New Strategies For HIV Vaccine

Source: La Jolla Institute for Immunology, California May 11, 2019

A new HIV vaccine delivery strategy appears to enhance the protective immune response in a preclinical model. Scientists at the La Jolla Institute for Immunology (LJI) have discovered that delivering an HIV vaccine in small doses over a series of days leads to a stronger immune response than when the same vaccine is given all at once. A similar escalating dose method could be the best way...

New antibody,UB-421, may suppress HIV for up to four months

Source: NIH/National Institute of Allergy and Infectious Diseases,US Apr 18, 2019

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-42...

FROM MEDICAL SPHERES BULLETINS

LATEST ON MEDICAL DEVICES